Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being ...

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Popular weight-loss drugs like Ozempic, Wegovy and Zepbound produce significantly less weight loss in real-world settings ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...